Background: Hypertension and type 2 diabetes mellitus (T2DM) synergistically deteriorate the vascular environment, making blood pressure reduction challenging, and substantially
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INTRODUCTION
Recent epidemiologic data underscore the ongoing difficulties associated with reducing blood pressure in diabetic hypertensive patients [1, 2] . Analysis of the International Survey Evaluating Microalbuminuria Routinely by Cardiologists in Patients with Hypertension (I-SEARCH) survey, for example, showed that blood pressure control rates in diabetic patients were very low with only 19% of men and 16% of women reaching control, even though 93.5% of patients in the whole cohort were being treated and most diabetic patients were taking between two and three drugs [2] . These data suggest that the problem with blood pressure control in diabetic patients is no longer lack of treatment and that our focus needs to turn toward improving treatment strategies. [3] . In line with guidelines, combination treatment with perindopril/indapamide is well suited for the treatment of diabetic patients: perindopril is a long-acting angiotensin-converting enzyme (ACE) inhibitor that has been proven to be nephroprotective [4] and indapamide is a metabolically neutral diuretic with mild natriuretic effects [5] . Treatment with perindopril/indapamide is also supported by extensive data from clinical trials [4, [6] [7] [8] [9] [10] [11] and in particular this combination has been shown to reduce mortality and vascular events in patients with T2DM [12] . therefore, exclusion criteria were not defined.
MATERIALS AND METHODS
Additional antihypertensive treatments (alpha-1-antagonist, beta-blocker, calcium channel blocker, centrally acting agent) could be maintained or added at the physician's discretion.
Office blood pressure and heart rate were measured at baseline, 1 month, and 3 months using validated oscillometric manometers.
Blood pressure control rates for diabetic patients were defined according to the 2013 ESH/ESC guidelines as an office systolic blood pressure (SBP)/diastolic blood pressure (DBP) \140/85 mmHg [17] . Blood pressure control rates for patients with pre-diabetes were defined as office SBP/DBP \140/90 mmHg.
Baseline Fig. 2a, b) . Mean daytime, nighttime, and 24-h blood pressure as well as mean 24-h pulse pressure, mean arterial pressure, and mean 24-h heart rate decreased significantly over the course of the 3 months of treatment (p\0.001; Fig. 2a, b) . In patients previously treated with ACE inhibitor ± HCTZ (n = 67) or ARB ± HCTZ (n = 10), mean 24-h blood pressure decreased by 23.4 ± 13.9/11.5 ± 9.7 and 22.3 ± 8.7/ 10.4 ± 13.2 mmHg, respectively (p\0.001) (Fig. 2c ).
RESULTS

Tolerability and Safety after 3 Months of Treatment with Perindopril/ Indapamide
Treatment was well tolerated. Thirty-six drugrelated adverse events occurred. Ankle edema occurred in 11 patients (0.4% of patients) and was reported most frequently, followed by dizziness (n = 7; 0.3% of patients), and cough (n = 6; 0.2% of patients). Seven serious adverse events occurred, none of which was treatment related: death of unspecified cause (n = 2), transient ischemic attack (n = 2), aorta stenosis diagnosed during study (n = 1), and worsening congestive heart failure (n = 2).
Between baseline and 3 months, mean
changes in laboratory parameters were significant for total cholesterol (-0.7 ± 0.9 mmol/L), LDL-C (-0.4 ± 0.7 mmol/L), triglycerides (-0.4 ± 1.3 mmol/L), serum uric acid (-18.2 ± 62.9 lmol/L), fasting blood glucose (-0.6 ± 1.0 mmol/L), and serum creatinine by (-3.9 ± 14.1 lmol/L) (for all p\0.001, uric acid p = 0.004, serum creatinine p = 0.04; Fig. 3 ). Changes were not significant for serum potassium (-0.04 ± 0.4 mmol/L), and HDL-C (?0.05 ± 0.3 mmol/L). These results were obtained against a background of stable concomitant treatment, including statins, aspirin, and antidiabetics ( Table 2 ).
DISCUSSION
The PICASSO study was designed to provide physicians with data that are directly relevant to daily medical practice and to the challenges associated with treating hypertension. In this T2DM subgroup analysis, we analyzed blood pressure data in patients with T2DM or prediabetes to determine if perindopril 10 mg/ indapamide 2.5 mg may offer an efficacious and well-tolerated alternative to previous unsuccessful antihypertensive treatments. Overall, these patients constitute a difficult-totreat cohort in which 65% of patients were obese and 62% of patients had grade 2 or 3 hypertension despite ongoing treatment.
Significant decreases in office blood pressure and ambulatory blood pressure were noted after 3 months of treatment and 69% of patients reached blood pressure control. As in the full PICASSO trial, treatment was well tolerated and was associated with improvements in laboratory parameters.
In this study, significant decreases in office blood pressure occurred regardless of baseline blood pressure: -19.2/9.4 mmHg in patients with grade 1 hypertension and -45.1/ 21.5 mmHg in patients with grade 3 hypertension. As decreases in SBP of 10 mmHg are associated with reductions in risk of diabetes-related complications (-12%), diabetes-related deaths (-15%), and myocardial infarction (-11%) [18] , these data suggest that treatment with perindopril/ indapamide would have a clinically meaningful long-term impact. Ambulatory SBP and pulse pressure are independent predictors of cardiovascular risk [19, 20] and blood pressure variability over the course of a day has significant impact on target organ damage and cardiovascular risk in hypertensive patients [21, 22] . The combination of perindopril/ indapamide has been shown to smooth the blood pressure curve and indapamide in monotherapy has previously been shown to reduce 24-h SBP variability [7, 23] . In this study, significant reductions in 24-h blood pressure, daytime blood pressure, nighttime blood pressure, 24-h pulse pressure, and 24-h mean arterial pressure occurred after 3 months of treatment with perindopril/indapamide. A longer-term study in a real-life setting would be needed to determine the effects on organ damage and cardiovascular risk.
For diabetic patients, treatment with ACE inhibitors
is recommended due to their proven cardioprotective and nephroprotective effects. This recommendation was recently confirmed once again in a meta-analysis [24] .
Combination with diuretics may help counterbalance the salt-retaining effects of diabetes and inhibit compensatory feedback loops. Within these therapeutic classes, careful choice of antihypertensive treatment is essential as drugs have different efficacy and tolerability profiles due to differences in molecular structure, pharmacokinetics, and pharmacodynamics. The British Society of Hypertension, for example, has recently highlighted the fact that diuretics differ greatly among themselves by recommending that indapamide or chlorthalidone be prescribed rather than HCTZ, which is associated with significantly poorer outcomes and an increased risk of mortality [25] . Furthermore, decreases in blood pressure presented herein support treatment with combination of perindopril/indapamide and the recommendation for combination therapy. Thiazide diuretics, due to their unwanted effects on carbohydrate, lipid uric acid, and electrolyte metabolism, are no longer the preferred choice for treatment of hypertensive patients with T2DM or pre-diabetes [25, 26] . Indapamide, however, is a thiazide-like sulfonamide and has been shown to be metabolically neutral in a wide range of patients including diabetic ones [11, 27, 28] . In this study, metabolic neutrality of indapamide is reflected in the improvement of total cholesterol, fasting glucose, and triglyceride levels that were obtained without any changes of other concomitant treatment with lipid lowering agents, or with antidiabetics. This is likely to be due to a decrease in dysmetabolic effects after discontinuation of treatments such as HCTZ or beta-blockers, e.g., atenolol. The lack of effect of treatment on serum potassium levels may reflect the fact that perindopril and indapamide have opposing action on potassium metabolism: ACE inhibitors may increase while thiazides-type diuretics decrease the plasma level of potassium by opposing action on renal excretion.
Fig. 2 a, b
Change in ambulatory blood pressure (n = 93) after 3 months of treatment with fixed-dose combination of perindopril 10 mg/indapamide 2.5 mg: diabetes subgroup analysis of the PICASSO trial. c Ambulatory blood pressure according to previous treatment. ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, DBP diastolic blood pressure, HCTZ hydrochlorothiazide, NS not significant, SBP systolic blood pressure, SD standard deviation
Study Limitations
The overall decrease in blood pressure observed in this trial was similar to the one observed in the whole cohort (-27/-13 mmHg) [14] . The blood pressure reduction data noted herein needs to be considered in the context of reallife everyday practice rather than that of randomized controlled studies, and need to be interpreted with the knowledge that the data most likely include some degree of placebo effect. To reflect real-life practice, specific criteria were not predefined for enrollment in the ambulatory blood pressure monitoring substudy, and as a result, the patients had, on average, more comorbidities than those in the whole cohort. These data should not be extrapolated to the whole cohort. Among limitations it has to be mentioned that no data were obtained for the duration of T2DM.
CONCLUSIONS
The PICASSO study was designed to provide physicians with data that are directly relevant to daily medical practice and to the challenges associated with treating hypertension. The data from this T2DM subgroup analysis of the main data of PICASSO study suggest that perindopril 
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